Date & Time of Session - 12/3/25 - from 2:30 - 3:30PM

Overview
GLP-1 receptor agonists and dual agonists, initially developed for type 2 diabetes, have transformed obesity pharmacotherapy by producing substantial and sustained weight loss along with cardiometabolic benefits. Beyond glycemic control, these agents are now supported by evidence for reducing cardiovascular events and showing promise in conditions such as nonalcoholic fatty liver disease and sleep apnea. As their indications expand and real-world use increases, clinicians need up-to-date knowledge on efficacy, safety, and practical considerations to optimize outcomes in obesity and related chronic diseases.

Despite its increasing prevalence, Latent Autoimmune Diabetes in Adults (LADA) remains widely misunderstood and frequently misdiagnosed as Type 2 diabetes. This diagnostic confusion often leads to delayed or ineffective treatment, as standard oral medications or injectables for Type 2 diabetes eventually prove ineffective for LADA's autoimmune progression. Correctly identifying LADA is crucial for mitigating severe health risks, such as diabetic ketoacidosis, and allows for earlier, more appropriate insulin therapy and beta-cell preservation. This presentation will highlight the need for increased awareness among healthcare providers to improve diagnostic accuracy and promote optimal long-term outcomes associated with diabetes.

Objectives
Upon completion of this activity, the participant will be able to:
1. Identify FDA approved GLP-1 receptor agonists and dual agonists approved for use in weight management and summarize their indications. 
2. Recommend the most appropriate GLP1 receptor agonist or dual agonist for a patient with obesity considering efficacy, safety and comorbid conditions. 
3. Explain the underlying autoimmune mechanism that causes destruction of beta cells in Latent Autoimmune Diabetes in Adults (LADA).
4. Contrast pharmacologic management approaches and the distinguishing diagnostic markers for Latent Autoimmune Diabetes in Adults (LADA) relative to Type 1 and Type 2 diabetes.

Target Audience
Pharmacists, physicians, nurses, fellows and residents

Speaker
Olivia Makara, PharmD 
Sara Sans, PharmD
PGY1 Pharmacy Resident 
Norton Children’s Hospital
Louisville, Kentucky

Session date: 
12/03/2025 - 3:00pm EST to 01/31/2026 - 11:59pm EST
Add to calendar: 
  • 1.00 ACPE

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

  • 1.00 AMA PRA Category 1 Credit™

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC (UK Healthcare CECentral)

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour(s).

  • 1.00 IPCE

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

  • 1.00 Participation
    UK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.
Please login or register to take this course.
Faculty List: 
Speaker(s)

Olivia Makara, PharmD

has no relevant financial relationships to disclose at this time.

Sara Sans, PharmD

has no relevant financial relationships to disclose at this time.